Wheeler et al. prospectively evaluated patients surgically treated (with no EGFR-directed therapy) for SCCHN and patients treated with radiation plus cetuximab, an EGFR-targeting MoAb [12]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.